A New FDA Program
The FDA launched a neuroscience program on October 22, 2026, beginning with an initiative focused on Alzheimer’s prevention.
Three Centers, One Effort
It combines scientific and regulatory expertise from FDA’s drug, biologics, and device centers.
A Broader Neuroscience Scope
Beyond Alzheimer’s, NAIN covers brain and nervous system conditions, including neurologic and psychiatric disorders, substance use disorders, and pain.
Challenges in Product Development
The FDA cites limited knowledge of underlying biology, varied disease presentations, and difficulty showing meaningful clinical benefit as development obstacles.
Tools May Address Challenges
Biomarkers, digital health technologies, and other development tools may help address challenges; the announcement does not establish any preventive benefit.
What Prevention Studies Will Explore
The accelerator will explore prevention-trial populations, stage-appropriate endpoints, and evidence needed to show prevention or delayed cognitive decline due to Alzheimer’s.
No New Treatment Announced
The announcement launches product-development work, not a newly approved preventive treatment or a change in individual patient care.
Read More From the FDA
Read the FDA announcement for details on NAIN, its Alzheimer’s Prevention Accelerator, and the agency’s planned collaboration.